The 2012 Shenzhen Innovation Committee Innovation Funding Project declared by our company was successfully approved.

The funded project of ISKCON is a concrete action to strengthen Shenzhen's technology city and focus on the development of strategic emerging industries. Under the advocacy of relevant leaders in Shenzhen, Shenzhen will provide strong support and support for innovative international cutting-edge technologies, regardless of policy, taxation, capital, personnel and many other aspects of support or preference, and will continue In order to build Shenzhen into a gathering place for high-end biomedical industries in China, a number of influential and effective pharmaceutical products at home and abroad have been introduced to serve the majority of patients.

In this context, because our company owns the internationally leading ACTL targeted anti-tumor cell immune technology, has obtained domestic and foreign patents, has mastered the core technology and is leading the international level, so from the government to the industry experts all support this technology, hope ACTL technology plays a role in catching up with developed countries in the fields of scientific research and clinical application, striving for international voice, and improving the level of domestic tumor treatment and scientific research strength. I believe that in the near future, the company will definitely take the lead in the field of domestic tumor biotherapy by virtue of its technical advantages, talent advantages, team cooperation advantages, and market advantages!